Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
OJEMDA (TOVORAFENIB) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
OJEMDA
NDA
Get alerts
TOVORAFENIB | N218033 | DAY ONE BIOPHARMACEUTICALS INC
1 strength
2 unique patents
2 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
2 unique patents, 2 exclusivities by expiration date
Active (2)
Today
Exclusivity
2027
2028
2029
2030
2031
2032
2033
2034
2035
Today
8293752
Aug. 4, 2031
10426782
Jun. 23, 2035
NCE
Apr. 23, 2029
ODE-478
Apr. 23, 2031
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 25MG/ML
RLD
2 patents
2 exclusivities
▴
FOR SUSPENSION;ORAL | Approved: Apr 23, 2024
Patents (2)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
8293752
Aug 4, 2031
—
Yes
Yes
—
—
10426782
Jun 23, 2035
—
—
Yes
—
—
Exclusivities (2)
Code
Date
Status
NCE
Apr 23, 2029
Active
ODE-478
Apr 23, 2031
Active